Clinical Trial Update: First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study evaluating the safety and tolerability of a single subcutaneous dose of SAR441255 in lean to overweight adults; study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overweight

Drugs mentioned

• SAR441255

Snippet

Sponsor: Sanofi | Conditions: Overweight, Healthy Subjects | Phase 1 | Status: COMPLETED